AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Isofol Medical

Major Shareholding Notification Jul 27, 2022

3063_iss_2022-07-27_4653e7f0-18dd-4b59-9e02-0ab22397f0ad.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Issuer Isofol Medical AB (publ)

Holder

Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension

Instrument
------------
Instrument Aktier
Before the transaction
Shares Data not given
Data not given
Voting rights
Transaction
Reason for major shareholding notification Sell
Date 26/07/2022
Limit for number of shares 5 %
Limit for number of votes 5 %
After the transaction
Quantity
Shares 8,074,275
Directly held voting rights 0
Indirectly held voting rights 8,074,275
Percentage
Directly held shares 4.99907 %
Directly held voting rights 0 %
Indirectly held voting rights 4.99907 %

Resulting distribution of total holdings

Percentage of voting
rights:
Number of underlying
shares:
Shares 4.99907 % 8,074,275
Instruments - FITA Ch. 4, section 2, first
paragraph, line 2
Instruments - FITA Ch. 4, section 2,
first paragraph, line 3
- Physically settled
- Cash settled 0.03691 % 59,613
Total 5.03598 % 8,133,888

Group total holdings

Voting rights 8,133,888 Percentage of voting rights 5.03598

Notes (other relevant informations according to law)

Aktierna, samt övriga instrument enligt LHF 4 kap, 2§ första stycket 1 och finansiella instrument enligt LHF 4 kap. 2§ första stycket 3 innehas av Försäkringsaktiebolaget Avanza Pension som är ett helägt dotterbolag till Avanza Bank Holding AB (publ). Det är försäkringskunder som via depåfullmakt har avyttrat de aktuella aktierna.

Published

27/07/2022 09:31

Contact

Name Magnus Westerman

Email [email protected]

*Source of information has chosen not to submit the data

[email protected] Tfn 08-408 980 37 Fax 08-24 39 25

Talk to a Data Expert

Have a question? We'll get back to you promptly.